SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3557 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3282I was expecting UK trial to read out data soon? get ROW sales going and controlBiotechwantabe14/21/2021
3281Additional down side to adoption of SC is 4 jabs/person. Lower dose my solve tBiotechwantabe-4/13/2021
3280Agreed, even if it does not impact the finances if it helps the world return to Felix B-4/13/2021
3279As it has been since the beginning, the timing doesn't seem to align right fCuttingEdge Bio-4/13/2021
3278Even if the EUA is updated, will this be enough to increase uptake? Any idea onFelix B-4/12/2021
3277Got it! I apparently misunderstood your point in the prior thread.DewDiligence_on_SI-4/12/2021
3276No, this was a study done in an entirely different setting. I previously argued CuttingEdge Bio-4/12/2021
3275Looks like REGN came through with the outcomes data for the subcutaneous formulaDewDiligence_on_SI-4/12/2021
3274Will it take fda 5-6w to approve for EUA? PHASE 3 PREVENTION TRIAL SHOWED 81% RBiotechwantabe-4/12/2021
3273Geomap for COVID. Data doesn’t predict another wave. Hoping the can push throBiotechwantabe-3/31/2021
3272<REGN needs to develop a subcutaneous formulation.> They are working on itMiljenko Zuanic-3/29/2021
3271Yeah, that makes sense. I'd agree with that.CuttingEdge Bio-3/25/2021
3270If [REGN] can show the PK is sufficiently similar and the viral-load impact is tDewDiligence_on_SI-3/24/2021
3269Do you believe the fact that [PFE’s phase-1 drug is] old and originally for SARSDewDiligence_on_SI-3/24/2021
3268Is it really viable to run ANOTHER trial like this one that just read out on thoCuttingEdge Bio-3/24/2021
3267Do you believe the fact that it's old and originally for SARS has important CuttingEdge Bio-3/24/2021
3266A few pills are easier to swallow than getting hooked up to an IV. If it survivA.J. Mullen-3/23/2021
3265Oops again! PFE’s PF-07321332 (oral) and PF-07304814 (IV) are two formulations oDewDiligence_on_SI13/23/2021
3264You're correct—my bad. The oral drug in today's PR is called PF-07321332DewDiligence_on_SI-3/23/2021
3263That link discusses a trial started in September for an IV administered drug. TA.J. Mullen-3/23/2021
3262BTW, PFE's COVID (protease inhibitor) antiviral in phase-1 is a SARS drug frDewDiligence_on_SI-3/23/2021
3261REGN needs to develop a subcutaneous formulation. How difficult is that? PresumA.J. Mullen-3/23/2021
3260Lower doses may lead to additional revenue?I would say that convincing outcomes DewDiligence_on_SI-3/23/2021
3259Dose-ranging Virology Trial A companion dose-ranging Phase 2 trial of 803 outpatBiotechwantabe-3/23/2021
3258REGN needs to develop a subcutaneous formulation.DewDiligence_on_SI-3/23/2021
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News